Arundhati interviewed Sarah Boyce, CEO of Avidity Biosciences. In October 2019, Sarah Boyce joined Avidity as President and CEO, and she serves as a member of the board of directors. Ms. Boyce brings to Avidity extensive operational, commercial and leadership experience in the life sciences industry and has built global organizations, bringing a number of innovative therapies including Tegsedi®, Waylivra®, Soliris®, Gleevec® and Tasigna® to patients.

Episode Resources

• Connect with Arundhati Parmar
• [email protected]
• https://twitter.com/aparmarbb?lang=en
• https://medcitynews.com/
• Connect with Sarah Boyce
• https://www.linkedin.com/in/sarah-boyce-7775808/
• http://www.aviditybiosciences.com/about-us/